To obtain a new compound inhibiting the binding of fibrinogen to the corresponding receptor and useful for the treatment of thromboses, apoplexy, cardiac infarct, ischemia, inflammations, arteriosclerosis, acute renal failure and others.
This compound is expressed by formula I [X is O, S, NH or NA; A is expressed by formula II or the like; R1 is expressed by formula III or the like; R2 and R3 are each H, A or benzyl; A is an alkyl; B is H, A, benzyl or the like; (m) and (r) are each 0-4] or a salt thereof, e.g. 3-(4- amidinophenyl)-5-(4-ethoxycarbonyl-4-ethoxycarbonylmethylpiperidinomethyl) oxazolidin-2-one. The compound of formula I is obtained by subjecting one of functional derivatives thereof to solvolysis or to treatment with a hydrogenolysis reagent so as to release the objective compound from the derivative. Also, the compound of formula I is obtained e.g. by reacting a compound of formula IV (Z is Cl, Br, I, OH or the like) with a compound of the formula H-Y. The daily dose of this compound is preferably 0.1-20 mg/kg.
HORUSUTO JIYURASUTSUIKU
PEETAA RADATSUTSU
HANSU BUYURUTSUIGAA
ZABIINE BERUNOTAATOODANIEROFUS
GUIDO MERUTSUAA
Next Patent: 3-ALKOXYCARBONYL-THIADIAZINONE COMPOUND